{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:05:29Z","timestamp":1790661929257,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Corticosteroids (CS) are commonly used as bridging therapy in ulcerative colitis (UC), but whether baseline CS use modifies the subsequent efficacy of advanced therapies remains unclear. With differing mechanisms across drug classes, it is uncertain whether CS impact on outcomes is consistent or drug-class-dependent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Web of Science, and Cochrane Library for CS-stratified randomized controlled trials (RCTs) comparing active drugs with placebo in moderate-to-severe UC. After deduplication, studies were selected per predefined criteria. Bias risk was assessed with the Cochrane tool. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model; robustness was tested by leave-one-out sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten RCTs (7 publications, 6,286 patients) were included. Overall, CS-na\u00efve patients showed significantly higher rates of endoscopic improvement (RR\u2009=\u20091.91, 95% CI: 1.33\u20132.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%), symptom relief (RR\u2009=\u20091.63, 95% CI: 1.16\u20132.29,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) and clinical remission (RR\u2009=\u20091.50, 95% CI: 1.03\u20132.19,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03, I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) than CS users during induction; no significant differences were observed for other efficacy endpoints. This overall trend masked marked heterogeneity by drug class. IL-23 inhibitors exhibited a pronounced advantage in non-CS users across multiple endpoints, including clinical remission, clinical response, and endoscopic improvement. S1P modulators yielded the largest effect size for histologic\u2013endoscopic mucosal improvement (RR\u2009=\u20093.04, 95% CI: 1.18\u20137.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). No significant differences were found between groups in adverse events, serious adverse events, discontinuations, infections, acne, or CPK elevation, even with CS use up to 52 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline CS status may influence the efficacy of advanced therapies in UC. IL-23 inhibitors appeared to benefit CS-na\u00efve patients across multiple endpoints, whereas JAK inhibitors showed a numerical but nonsignificant advantage in CS-exposed patients. Short-term concomitant CS did not significantly increase adverse events, supporting the clinical acceptability of CS bridging in highly active disease. These findings support stratified reporting in future RCTs and call for prospective studies to validate these observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251248449<\/jats:ext-link>\n                      , identifier, CRD420251248449.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1938069","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:48:29Z","timestamp":1790660909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stratified by baseline corticosteroid use: which advanced therapy works best for whom in ulcerative colitis?"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengqing","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/17474124.2019.1604219","article-title":"A current overview of corticosteroid use in active ulcerative colitis","volume":"13","author":"Salice","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British society of gastroenterology consensus guidelines on the management of inflam-matory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/MIB.0000000000001261","article-title":"Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis","volume":"23","author":"Cross","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e001220","DOI":"10.1136\/bmjdrc-2020-001220","article-title":"Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated in-flammatory diseases: a population-based cohort analysis","volume":"8","author":"Wu","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/apt.15497","article-title":"Assessment of steroid use as a key performance indicator in inflammatory bowel dis-ease-analysis of data from 2385 UK patients","volume":"50","author":"Selinger","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000549339","article-title":"Questionnaire survey on the current status of advanced therapy for inflammatory bowel disease in Asia","volume":"107","author":"Toya","year":"2025","journal-title":"Digestion"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1724448","DOI":"10.3389\/fmed.2025.1724448","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials","volume":"12","author":"He","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110472","DOI":"10.4292\/wjgpt.v16.i4.110472","article-title":"Emerging role of janus kinase inhibitors in ulcerative colitis management","volume":"16","author":"Ahsan","year":"2025","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2025-7-3","DOI":"10.7573\/dic.2025-7-3","article-title":"Sphingosine-1-phosphate receptor modulators in ulcerative colitis - a narrative review of current evidence and practical considerations","volume":"14","author":"Kuriakose Kuzhiyanjal","year":"2025","journal-title":"Drugs Context"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12967-025-07385-3","article-title":"Research progress in molecular targeted therapy for inflammatory bowel disease","volume":"24","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.cgh.2025.05.019","article-title":"Appropriate use and complications of corticosteroids in inflammatory bowel dis-ease: a comprehensive review","volume":"23","author":"Feuerstein","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"Br Med J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S2468-1253(25)00198-0","article-title":"Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in east Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"10","author":"Wu","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"jjae150","DOI":"10.1093\/ecco-jcc\/jjae150","article-title":"Etrasimod corticosteroid-free efficacy, impact of concomitant corticosteroids on efficacy and safety, and corticosteroid-sparing effect in ulcerative colitis: analyses of the ELEVATE UC clinical program","volume":"19","author":"Sands","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"jjaf025","DOI":"10.1093\/ecco-jcc\/jjaf025","article-title":"Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002250","article-title":"S1p receptor modulators improve clinical outcomes in ulcerative colitis: a stratified meta-analysis by prior biological use, corticosteroid exposure, and disease characteristics","author":"Tanriverdi","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70073","DOI":"10.1002\/jcc5.70073","article-title":"Efficacy of advanced medical therapies in patients with moderately to severely active ulcerative colitis: a systematic review and meta-analysis","volume":"1","author":"Visser","year":"2026","journal-title":"JCC Plus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American gastroenterological association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e240225","DOI":"10.57264\/cer-2024-0225","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysis","volume":"14","author":"Jairath","year":"2025","journal-title":"J Comp Effect Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/jcm14165789","article-title":"Efficacy of biologic agents and small molecules for endoscopic improvement and mucosal healing in patients with moderate-to-severe ulcerative colitis: systematic review and meta-analysis","volume":"14","author":"Mademlis","year":"2025","journal-title":"J Clin Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1938069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:48:30Z","timestamp":1790660910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1938069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1938069"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1938069","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1938069"}}